within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05B_AntivaricoseTherapy.C05BB03_InvertSugar;

model InvertSugar
  extends Pharmacolibrary.Drugs.ATC.C.C05BB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C05BB03</td></tr><td>route:</td><td></td></tr><tr><td>n-compartments</td><td>0</td></tr></table><p>Invert sugar is a mixture of glucose and fructose produced by the hydrolysis of sucrose. It has been used historically as a plasma volume expander and as a source of carbohydrate calories in parenteral nutrition, particularly when glucose administration is undesirable (e.g., hereditary fructose intolerance). It is not a commonly approved drug for clinical use today.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters for invert sugar (ATC code C05BB03) could be found in published literature for administration as a medicinal product in humans.</p><h4>References</h4><ol><li><p>Roemer, E, Schorp, MK, Piadé, JJ, Seeman, JI, Leyden, DE, &amp; Haussmann, HJ (2012). Scientific assessment of the use of sugars as cigarette tobacco ingredients: a review of published and other publicly available studies. <i>Critical reviews in toxicology</i> 42(3) 244–278. DOI:<a href=\"https://doi.org/10.3109/10408444.2011.650789\">10.3109/10408444.2011.650789</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22263649/\">https://pubmed.ncbi.nlm.nih.gov/22263649</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end InvertSugar;
